Search results for: 'Deep Learning Interfaces: Future of AI (Technical Insights)'

As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...

A major challenge in drug discovery is the limited number of gene targets that can be targeted for the development of a drug molecule. Only close to 400 genes are proven targets for US FDA-approved drugs. 80% of human genes are unexplored as targets, and some are considered undruggable. The identification and the selection of novel drug targets (p...

In an increasingly independent, mobile and do-it-yourself world, healthcare alone remains rooted in a centralized, professional-controlled setting. However, emerging global megatrends necessitate the need for decentralization of healthcare services and patient empowerment. This research service showcases emerging trends in home healthcare and throw...

09 Sep 2024  |  Global  |  Technology Research

AI-based Drug Repurposing Market, Growth Opportunities, Global, 2024-2029

AI-based Drug Repurposing is emerging as a new and faster approach to bringing drugs to patients.

Infographics

×

This study analyzes the emergence of AI-based drug repurposing and examines the factors driving and hindering adoption. The limitation of traditional drug discovery has led to the growing interest in AI -based drug repurposing, which offers numerous advantages in terms of time, speed, and cost. AI-based drug repurposing has been explored across dif...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

The future of three-dimensional bioprinting (3DBP) and its transformation of the healthcare sector will be determined by the breadth and depth of its application potential, and its ability to unleash a whole new world of application segments. From printing a tissue or cells to developing human organs, 3DBP has demonstrated capability in the world o...

The impact of the digital revolution continues to disrupt the healthcare industry. This includes evolving digital technological capabilities, new business models and marketing approaches, the healthcare consumerism trend, the changing regulatory environment, and competitive threats from new market entrants, such as digital-native companies—particul...

This Frost & Sullivan research service discusses advances in AI integration in Molecular Diagnostics, highlights key advantages of incorporating AI in the diagnostics workflow and roadblocks that have prevented it from becoming mainstream. While AI is widely used in radiology- and pathology-based diagnostics, its adoption is gradually increasing in...